The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery

Overview

Traditionally, pain control methods based on narcotic analgesics have been used to control severe pain after surgery, but this has resulted in side effects such as vomiting, constipation, dizziness, mental confusion due to drugs, and respiratory depression. This slowed the recovery of the patient after surgery and increased the duration of hospitalization, which had a negative impact on the patient 's prognosis. In addition, research has been conducted on the use of various painkillers in a variety of ways over the past decade to reduce the dose of narcotic analgesics and to increase the effectiveness of pain control, since studies of anesthetics and narcotic analgesics have shown immunosuppressive effects. This study investigate the effect of multimodal analgesics for postoperative pain control on immune function amd prognosis in patients undergoing laparoscopic colorectal cancer resection.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: December 31, 2019

Interventions

  • Drug: IV ketamine/lidocaine/IV PCA apply
    • In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
  • Drug: IV PCA only apply
    • IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.

Arms, Groups and Cohorts

  • Experimental: IV ketamine/lidocaine/IV PCA (MA) group
    • In addition to basic anesthetic methods, multimodal analgesia with IV ketamine, lidocaine and IV PCA apply
  • Active Comparator: IV PCA only (CA) group
    • In addition to basic anesthetic methods, only IC PCA apply for pain control

Clinical Trial Outcome Measures

Primary Measures

  • natural killer cell cytotoxicity
    • Time Frame: postoperative day #3
    • Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).

Participating in This Clinical Trial

Inclusion Criteria

1. elective laparoscopic colorectal resection due to colorectal cancer 2. curative, resectable operation 3. ASA classification Ⅰ-Ⅲ Exclusion Criteria:

1. elective co-operation due to distance metastasis 2. preoperative chemo/radiation therapy 3. drug allergy to opioid, tramadol, local anesthetics 4. MAOi medication (within 14 days of surgery) 5. decreased hepatic/renal function 6. Patients who can not read the consent form or are not fluent in Korean (illiterate, foreigner 7. pregnant, lactating women 8. palliative surgery

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Yonsei University
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.